Epigenetic changes in patients with multiple sclerosis

Nat Rev Neurol. 2013 Jan;9(1):35-43. doi: 10.1038/nrneurol.2012.226. Epub 2012 Nov 20.

Abstract

Epigenetic changes influence gene expression without altering the DNA sequence. DNA methylation, histone modification and microRNA-associated post-transcriptional gene silencing are three key epigenetic mechanisms. Multiple sclerosis (MS) is a disease of the CNS with both inflammatory and neurodegenerative features. Although studies on epigenetic changes in MS only began in the past decade, a growing body of literature suggests that epigenetic changes may be involved in the development of MS, possibly by mediating the effects of environmental risk factors, such as smoking, vitamin D deficiency and Epstein-Barr virus infection. Such studies are also beginning to deliver important insights into the pathophysiology of MS. For example, inflammation and demyelination in relapsing-remitting MS may be related to the increased differentiation of T cells toward a T-helper 17 phenotype, which is an important epigenetically regulated pathophysiological mechanism. In progressive MS, other epigenetically regulated mechanisms, such as increased histone acetylation and citrullination of myelin basic protein, might exacerbate the disease course. In this Review, we summarize current knowledge on the role of epigenetic changes in the pathophysiology of MS.

Publication types

  • Review

MeSH terms

  • Citrulline / metabolism
  • DNA Methylation / drug effects
  • DNA Methylation / genetics
  • Disease Progression
  • Epigenesis, Genetic / genetics*
  • Forecasting
  • Gene-Environment Interaction
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Inflammation Mediators / metabolism
  • Lymphocyte Activation / genetics
  • Lymphocyte Activation / immunology
  • Macrophage Activation / genetics
  • Macrophage Activation / immunology
  • Multiple Sclerosis, Chronic Progressive / drug therapy
  • Multiple Sclerosis, Chronic Progressive / genetics*
  • Multiple Sclerosis, Chronic Progressive / immunology
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting / genetics*
  • Multiple Sclerosis, Relapsing-Remitting / immunology
  • Myelin Basic Protein / metabolism
  • Neurotransmitter Agents / metabolism
  • Oligonucleotides / therapeutic use
  • Risk Factors
  • T-Lymphocytes, Helper-Inducer / immunology

Substances

  • Histone Deacetylase Inhibitors
  • Inflammation Mediators
  • Myelin Basic Protein
  • Neurotransmitter Agents
  • Oligonucleotides
  • locked nucleic acid
  • Citrulline